|
C9ORF78 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62803104331033E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
5.18707299335119E-12 |
| Normal-vs-Stage2 |
1.69109000000001E-05 |
| Normal-vs-Stage3 |
3.33510996597397E-13 |
| Normal-vs-Stage4 |
8.27700130656694E-11 |
| Stage1-vs-Stage2 |
5.502200E-01 |
| Stage1-vs-Stage3 |
2.730200E-02 |
| Stage1-vs-Stage4 |
3.361000E-03 |
| Stage2-vs-Stage3 |
3.946600E-01 |
| Stage2-vs-Stage4 |
1.162830E-01 |
| Stage3-vs-Stage4 |
2.866000E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
3.10862446895044E-15 |
| Normal-vs-AfricanAmerican |
7.68950000000768E-05 |
| Normal-vs-Asian |
9.97040000005889E-07 |
| Caucasian-vs-AfricanAmerican |
6.068200E-01 |
| Caucasian-vs-Asian |
4.090000E-01 |
| AfricanAmerican-vs-Asian |
3.233000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.18036699806134E-12 |
| Normal-vs-Female |
1.79856129989275E-14 |
| Male-vs-Female |
6.036800E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
7.6394446324457E-12 |
| Normal-vs-Age(41-60Yrs) |
4.01112476566823E-12 |
| Normal-vs-Age(61-80Yrs) |
8.41549052665869E-13 |
| Normal-vs-Age(81-100Yrs) |
9.675000E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
8.954600E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
5.430200E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
2.138400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
7.055600E-02 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
2.526600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
6.859600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
4.753000E-04 |
| Classical-VS-Follicular |
2.885400E-01 |
| Classical-VS-Other |
6.833600E-01 |
| Classical-VS-Normal |
2.95419244622508E-12 |
| Tall-VS-Follicular |
3.809000E-04 |
| Tall-VS-Other |
2.212200E-02 |
| Tall-VS-Normal |
1.64235292032799E-12 |
| Follicular-VS-Other |
9.950800E-01 |
| Follicular-VS-Normal |
4.87699999995872E-06 |
| Other-VS-Normal |
6.922400E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
5.90183457660487E-12 |
| Normal-vs-N1 |
3.91499999086165E-09 |
| N0-vs-N1 |
1.658980E-01 |
|
|
